HIV Antiretroviral Allergy: Abacavir HLA Screening & Nevirapine DRESS

The PREDICT-1 trial, published by Mallal et al. in the New England Journal of Medicine in 2008, is the landmark study that established pharmacogenomic screening for drug allergy. The trial randomized 1,956 patients to HLA-B*57:01 screening before abacavir prescription versus standard care without screening. In the screening arm, HLA-B*57:01-positive patients were denied abacavir, resulting in zero immunologically confirmed hypersensitivity reactions (compared to 2.7 percent in the unscreened arm). Clinically suspected reactions also dropped from 7.8 to 3.4 percent. This trial directly led to the FDA mandating HLA-B*57:01 testing in July 2008 and represents the most successful pharmacogenomic intervention in drug allergy.

Abacavir rechallenge after documented hypersensitivity triggers a rapid and severe immune response because the patient's T cells are already primed against the altered-self peptides created by abacavir binding to HLA-B*57:01. On re-exposure, these memory T cells mount an immediate and overwhelming attack, causing anaphylaxis with cardiovascular collapse that can be fatal within hours. This is why desensitization is not an option for abacavir — unlike some drug allergies where gradual dose escalation can induce tolerance, the T-cell memory response to abacavir is too rapid and severe. The allergy must be permanently documented in all medical records and pharmacy systems.

The nevirapine CD4 paradox refers to the counterintuitive finding that patients with higher CD4 counts — indicating better immune function — have higher risk of nevirapine hepatotoxicity. Women with CD4 above 250 cells per microliter and men with CD4 above 400 have significantly elevated hepatotoxicity risk. This is the opposite of most drug toxicity patterns where immunocompromised patients fare worse. The mechanism likely involves more vigorous immune-mediated liver damage when the immune system is relatively intact. The FDA contraindicates nevirapine initiation above these CD4 thresholds, which is one reason nevirapine has been largely replaced by integrase inhibitors in first-line regimens.

Yes. Integrase strand transfer inhibitors (dolutegravir, bictegravir, raltegravir, cabotegravir) have substantially lower hypersensitivity signal than the older NNRTIs (nevirapine, efavirenz). Dolutegravir has rare reported hypersensitivity reactions, but the incidence is much lower than the 15 to 20 percent rash rate seen with nevirapine or the 15 percent rash rate with efavirenz. The DHHS 2022 guidelines recommend integrase inhibitor-based regimens as preferred first-line therapy, driven by both efficacy and tolerability advantages. This class shift has substantially reduced the clinical burden of antiretroviral allergy.

Darunavir contains a sulfa moiety (sulfonamide carbamate) which raises theoretical concern in patients with sulfonamide antibiotic allergy. However, darunavir lacks the N4 arylamine group that is the immunogenic determinant in antibiotic sulfonamides (sulfamethoxazole, sulfadiazine). Per the AAAAI 2022 Drug Allergy Practice Parameter, there is no established cross-reactivity between antimicrobial and nonantimicrobial sulfonamides. Clinical experience with darunavir in sulfa-allergic HIV patients has not demonstrated elevated hypersensitivity rates. Most HIV specialists prescribe darunavir to sulfa-labeled patients without additional precautions, though individual allergist consultation may be warranted after severe SCAR reactions.

HLA-B*57:01 prevalence varies significantly by ethnic background. It is found in approximately 5 to 8 percent of white European populations, about 2 to 3 percent of African American populations, and at lower frequencies in most Asian populations. In some populations such as Southwest Asian Indians, the prevalence may be higher. This variation means that abacavir hypersensitivity would be more common in populations with higher HLA-B*57:01 prevalence if screening were not performed. Regardless of population-level prevalence, individual testing is mandatory before prescribing abacavir because the consequences of a positive test result are absolute — abacavir must not be used.

Report any new rash to your HIV care provider immediately, especially within the first six weeks of starting or switching an antiretroviral regimen. Your provider will assess whether the rash is accompanied by systemic signs (fever, hepatitis, eosinophilia) that would indicate DRESS syndrome versus a mild isolated rash that may be tolerable with antihistamine support. For abacavir-containing regimens, any combination of fever, rash, nausea, or malaise should prompt immediate drug discontinuation until the reaction is evaluated. Never restart a medication that has been stopped for a suspected allergic reaction without explicit guidance from your HIV specialist.

Long-acting injectable antiretrovirals (cabotegravir plus rilpivirine as Cabenuva, given monthly or bi-monthly) have a favorable allergy profile. Injection site reactions (pain, swelling, nodules) are common and pharmacologic rather than immune-mediated. Systemic hypersensitivity to cabotegravir or rilpivirine is rare. The main consideration with long-acting formulations is that if a severe allergic reaction does occur, the drug cannot be immediately eliminated from the body as it can with oral medications — the intramuscular depot continues releasing drug for weeks. Patients with a history of severe drug allergy should discuss this risk-benefit consideration with their HIV specialist.